๊ฐ€์ž… ํ›„ ์ดˆ๋Œ€ ๋งํฌ๋ฅผ ๊ณต์œ ํ•˜๋ฉด ๋™์˜์ƒ ์žฌ์ƒ ๋ฐ ์ดˆ๋Œ€ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

Wall St Engine
@wallstengine
Fast, accurate, consistent stock market news, earnings highlights & more. By Brillinsight. Not financial advice.
๊ฐ€์ž… March 2022
999 ํŒ”๋กœ์ž‰ ์ค‘    224.6K ํŒฌ
THERMO FISHER SCIENTIFIC $TMO Q3โ€™26 EARNINGS HIGHLIGHTS ๐Ÿ”น Revenue: $12.14B (Est. $11.95B) ๐ŸŸข; +9% YoY ๐Ÿ”น Adj. EPS: $6.68 (Est. $6.40) ๐ŸŸข; +15% YoY ๐Ÿ”น Organic Revenue Growth: +6% Other Q3 Metrics: ๐Ÿ”น Adj. Oper Income: $2.97B (Est. $2.87B) ๐ŸŸข ๐Ÿ”น Adj. Net Income: $2.48B (Est. $2.38B) ๐ŸŸข ๐Ÿ”น Adj. Oper Margin: 24.5%; +120 bps YoY ๐Ÿ”น GAAP Oper Margin: 18.6%; +120 bps YoY ๐Ÿ”น Free Cash Flow: $2.12B; vs $1.84B LY Segment Revenue: ๐Ÿ”น Life Sciences Solutions: $2.72B; vs $2.59B LY ๐Ÿ”น Analytical Instruments: $2.00B; vs $1.89B LY ๐Ÿ”น Specialty Diagnostics: $1.10B; vs $1.17B LY ๐Ÿ”น Lab Products & Biopharma: $6.86B; vs $5.97B LY Key Updates: ๐Ÿ”น GAAP EPS: $4.64; +9% YoY ๐Ÿ”น Completed our previously announced divestiture of our microbiology business ๐Ÿ”ธ Cost of revenues adjustments: $0.02/share ๐Ÿ”ธ Selling, general and administrative expenses adjustments: -$0.06/share ๐Ÿ”ธ Restructuring and other costs: $0.54/share ๐Ÿ”ธ Amortization of acquisition-related intangible assets: $1.40/share ๐Ÿ”ธ Other income/expense adjustments: $0.04/share ๐Ÿ”ธ Income taxes adjustments: $0.07/share ๐Ÿ”ธ Equity in earnings/losses of unconsolidated entities: $0.02/share Comments: ๐Ÿ”ธ โ€œLooking ahead, weโ€™re well positioned to deliver an excellent 2026 as we continue to drive long-term value creation for all of our stakeholders and build an even brighter future for our company.โ€
๋” ๋ณด๊ธฐ